Loading...
Insights2021-01-12T11:48:07-05:00

The global impact of Precision Medicine Group.
As it happens.

Impact, observations, and insights on the evolving healthcare landscape.

Article: Cell & Gene Therapies: Opportunities for Innovation

Cell & Gene Therapy, Thought Leadership|

In recent years, the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are transforming the way diseases are treated but are also aiming to cure entirely new patient populations. 2021 saw record-breaking investments across the board, with a 16% increase from the previous year, totaling $23.1billion raised. However, the question remains as to whether this will continue in 2022. As public markets adjust and the economy recovers in early 2022, investments in the cell and gene therapy space may plateau.

(more…)

Key Takeaways: World EPA Congress 2022

Cell & Gene Therapy, Events|

Did you miss our presentation at this year’s World EPA Congress in Amsterdam? Precision experts Richard Macaulay (VP, Global Pricing and Market Access) and David Carr (Director, Global Pricing and Market Access) presented “Gene Therapies Market Access: Lessons From The Past, Future Best Practice” which analyzes the access success of launched gene therapies and draws best-practice learnings for future gene therapies.

(more…)

On-Demand Webinar: Planning for the Commercialization of Advanced Therapies

Cell & Gene Therapy, Events|

In January, the Alliance for Regenerative Medicine (ARM) released its State of the Industry Briefing which highlighted a record-breaking year for 2021. $23.1B raised for the advanced medicines sector (a 16% increase from 2020), 2,261 ongoing regenerative medicine clinical trials globally, and the evolution from treating and curing rare monogenetic diseases to more prevalent indications. Could we see 10-20 approvals each year by 2025?

(more…)

Load More Posts